SENS - Senseonics Holdings, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
3.61
-0.08 (-2.17%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.69
Open3.70
Bid0.00 x 800
Ask0.00 x 2900
Day's Range3.60 - 3.80
52 Week Range2.36 - 5.29
Volume1,393,697
Avg. Volume1,860,275
Market Cap635.457M
Beta (3Y Monthly)-0.50
PE Ratio (TTM)N/A
EPS (TTM)-0.65
Earnings DateNov 8, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.86
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    New Research Coverage Highlights QuinStreet, Senseonics, Ring Energy, Blue Apron, Second Sight Medical Products, and Real Goods Solar — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire5 days ago

    Senseonics Holdings, Inc. Schedules Third Quarter 2018 Earnings Release and Conference Call for November 8, 2018 at 4:30 p.m. Eastern Time

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it plans to release its third quarter 2018 financial results after market close on Thursday, November 8, 2018. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. (NYSE American: SENS) is a medical technology company focused on the design, development and commercialization of transformative glucose monitoring products designed to help people with diabetes confidently live their lives with ease.

  • Simply Wall St.19 days ago

    Do You Know Who Else Invests In Senseonics Holdings Inc (NYSEMKT:SENS)?

    The big shareholder groups in Senseonics Holdings Inc (NYSEMKT:SENS) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have Read More...

  • Are Options Traders Betting on a Big Move in Senseonics Holdings (SENS) Stock?
    Zackslast month

    Are Options Traders Betting on a Big Move in Senseonics Holdings (SENS) Stock?

    Investors need to pay close attention to Senseonics Holdings (SENS) stock based on the movements in the options market lately.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SENS earnings conference call or presentation 8-Aug-18 8:30pm GMT

    Q2 2018 Senseonics Holdings Inc Earnings Call

  • Senseonics Holdings (SENS) Reports Q2 Loss, Misses Revenue Estimates
    Zacks2 months ago

    Senseonics Holdings (SENS) Reports Q2 Loss, Misses Revenue Estimates

    Senseonics (SENS) delivered earnings and revenue surprises of -23.08% and -7.93%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Senseonics: 2Q Earnings Snapshot

    On a per-share basis, the Germantown, Maryland-based company said it had a loss of 23 cents. Losses, adjusted for non-recurring costs, were 16 cents per share. The medical technology company posted revenue ...

  • Business Wire2 months ago

    Senseonics Holdings, Inc. Reports Second Quarter 2018 Financial Results

    Senseonics Holdings, Inc. , a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, today reported financial results for the second quarter ended June 30, 2018.

  • ACCESSWIRE2 months ago

    Senseonics Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Senseonics Holdings, Inc. (NYSE MKT: SENS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30 PM Eastern ...

  • Business Wire2 months ago

    Senseonics Begins U.S. Commercialization of Eversense Continuous Glucose Monitoring System With First Shipment, First Users and First Policy Coverage

    Senseonics Holdings, Inc. (SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that the Eversense® CGM System is now available at trained clinics across the U.S. and physicians have begun sensor placements with patients. Concurrently, the company reported that its first commercial payer, Horizon Blue Cross Blue Shield of New Jersey and Horizon Healthcare of New Jersey, has added coverage of the Eversense System to its Medical Policy.

  • Investopedia3 months ago

    Penny Stocks to Watch for August 2018

    Penny stock pickers booked modest returns in these tough conditions, while trend followers and dart throwers took losses. The July penny stock list generated mixed returns, with precious metals and biotech headwinds limiting gains while a mid-month crude oil reversal undermined small energy plays.

  • Business Wire3 months ago

    Senseonics to Participate in the Canaccord Genuity Growth Conference

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced the company plans to participate in the upcoming Canaccord Genuity Growth Conference in Boston, MA. Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ Eversense System is a long-term, implantable device, which includes a small sensor, smart transmitter and mobile application.

  • Business Wire3 months ago

    Senseonics Holdings, Inc. Schedules Second Quarter 2018 Earnings Release and Conference Call for August 8, 2018 at 4:30 p.m. Eastern Time

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced that it plans to release its second quarter 2018 financial results after market close on Wednesday, August 8, 2018. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease.

  • Business Wire3 months ago

    Senseonics & Glooko Announce Partnership on Integrated Diabetes Management

    Senseonics Holdings, Inc. (SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced a partnership with Glooko, Inc, the leading diabetes data management company. The partnership enables integration of the long-term Eversense® branded continuous glucose monitoring (CGM) systems with Glooko’s diabetes data management platform.

  • Why Senseonics Holdings Is Up ~5.6% Today
    Market Realist4 months ago

    Why Senseonics Holdings Is Up ~5.6% Today

    Today, Senseonics Holdings (SENS) is trading higher than yesterday’s close of $4.43 per share. The stock was up ~5% in premarket trading and is trending higher since then. SENS stock registered a 52-week high of $5.29 on June 22, as the company received FDA pre-market approval for the sale of its Eversense CGM (continuous glucose monitoring) system, which is the first CGM with implantable sensor and continuous monitoring capability for up to three months.

  • 3 Best Diabetes Stocks of 2018 So Far
    Motley Fool4 months ago

    3 Best Diabetes Stocks of 2018 So Far

    These diabetes stocks gained at least 50% in the first half of the year. But can the momentum continue?

  • Implied Volatility Surging for Senseonics (SENS) Stock Options
    Zacks4 months ago

    Implied Volatility Surging for Senseonics (SENS) Stock Options

    Senseonics (SENS) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Business Wire4 months ago

    Senseonics Announces Closing of Public Offering of Common Stock

    Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the closing of a registered underwritten public offering of its common stock, which included the sale of additional shares of common stock upon full exercise of the underwriter’s option to purchase additional shares. Senseonics’ Eversense System is a long-term, implantable device, which includes a small sensor, smart transmitter and mobile application.

  • Business Wire4 months ago

    Senseonics Announces Pricing of Public Offering of Common Stock

    Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the pricing of a registered underwritten public offering of its common stock for proceeds of $130.0 million, before deducting estimated offering expenses payable by Senseonics. In addition, Senseonics has granted the underwriter a 30-day option to purchase up to an additional $19.5 million of shares of its common stock. A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was declared effective by the Securities and Exchange Commission (SEC) on April 19, 2018.

  • Business Wire4 months ago

    Senseonics Announces Public Offering of Common Stock

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it has commenced a registered underwritten public offering of $80 million of its shares of common stock. In addition, Senseonics has granted the underwriter a 30-day option to purchase up to an additional $12 million of its shares of common stock. All of the shares to be sold in the offering are to be sold by Senseonics.

  • Senseonics Launches the “Ever Mobile Clinic” – A Converted 18 Wheeler Training Facility to Tour United States
    Business Wire4 months ago

    Senseonics Launches the “Ever Mobile Clinic” – A Converted 18 Wheeler Training Facility to Tour United States

    Senseonics Holdings, Inc. (NYSE American: SENS) today announced the launch of the company’s Ever Mobile Clinic Tour, a program to bring hands-on diabetes device training and education directly to U.S. patients and healthcare professionals in their local areas via a custom-built 18-wheeler mobile training facility. The national education-based tour features the Ever Mobile Clinic, a mobile educational facility custom-built within a semi-truck to accommodate the education and training of healthcare professionals and patients in the use of the company’s recently approved Eversense® Continuous Glucose Monitoring (CGM) System.

  • Business Wire4 months ago

    Six-Month Data on Long-Term Eversense CGM System Show Sustained Accuracy in Longest Pediatric Continuous Sensor Study

    Senseonics Holdings, Inc. (SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced the presentation by third party researchers of new data from a clinical study evaluating the performance of the Eversense® XL Continuous Glucose Monitoring (CGM) system for up to 180 days in pediatrics and adults with diabetes. Findings were presented on June 22, 2018 at the American Diabetes Association’s (ADA) 78th Scientific Sessions. “This is the first study to examine any CGM system in a pediatric population for a period of continuous wear for more than 14 days,” said Dr. Ronnie Aronson, MD, FRCPC, FACE, primary investigator, endocrinologist and chief medical officer of LMC Diabetes & Endocrinology, Toronto, Canada.

  • ACCESSWIRE4 months ago

    Complimentary Technical Snapshots on Senseonics Holdings and Three More Medical Equipment Stocks

    Stock Research Monitor: EW, PBH, and VAR LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on SENS sign up now at www.wallstequities.com/registration . On Friday, June 22, 2018, ...